Friday, November 20, 2020

Will the AstraZeneca vaccine also tackle Pfizer and Moderna?

 The coronavirus vaccine developed by the University of Oxford and AstraZeneca was convicted of surviving and precipitating a similar immune response among all adults based on the preliminary findings of the phase two test run.

In addition, the study carried out on 560 healthy adults, including 240 individuals over the age of 70, found that the vaccine survived and produced similar immune responses among individuals over 56 and those between 18 and 18. 55 years.

Prior to this, Britain's leading pharmaceutical company AstraZeneca, in collaboration with the University of Oxford, disclosed that preliminary data showed their experimental vaccine had produced an immune response in both older and younger adults.

However, the Oxford vaccine candidate was found to cause few side effects and trigger an immune response in both parts of the immune system at all age ratings with low and standard dosages.

Preliminary results suggest that the vaccine known as ChAdOx1 nCoV-19 is reported to promote T-cell response within 14 days of the first dose injection, and antibody response within 28 days of the inhibiting dose. Scientists hope that T-cell retaliation plays a role in fighting the virus in the long term.

According to Dr. Maheshi Ramasamy, co-author of the study at the University of Oxford said that antibodies and T-cell countermeasures in older adults are predatory.